A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease
Table 3
Change in UPDRS scores seen following rasagiline administration.
Change in UPDRS
Study, year
Time of assessment (from the start of the study)
Treatment
Part II
Part III
Total
Comments
Barone et al. 2015
12 wk.
PBO
0.06 ± 0.32
0.42 ± 0.51
NR
—
RA
−1.37±0.35
−0.88 ± 0.56
NR
Hanagasi et al. 2011
12 wk.
PBO
−1.64 ± 3.59
−2.20 ± 4.05
NR
—
RA
−2.17 ± 3.95
−4.35 ± 5.21
NR
Hattori et al. 2019
26 wk.
PBO
2.32 ± 0.34
−0.48 ± 0.64
NR
—
RA
0.13±0.35
−4.47±0.67
NR
Hauser et al. 2014
18 wk.
PBO
0.3 ± 0.3
−1.6 ± 0.5
−1.2 ± 0.7
—
RA
−0.1 ± 0.3
−3.4±0.5
−3.6±0.7
Olanow et al. 2009
36 wk.
PBO
1.64 (1.43 to 1.85)
2.38 (1.96 to 2.79)
4.27±0.26
Estimates of change from baseline in UPDRS subscores at week 36. N = 588 (PBO), N = 286 (RA 1), N = 290 (RA 2)
Rascol et al. 2011a
RA 1 mg RA 2 mg
0.78 (0.49 to 1.06) −0.86±0.18 0.76 (0.47 to 1.04) −0.88±0.18
0.50 (−0.07 to 1.07) −1.88±0.35 0.20 (−0.37 to 0.76) −2.18±0.35
1.26 ± 0.36 1.11 ± 0.36
Schrempf et al. 2018
8 wk.
PBO
NR
NR
NR
N = 17 (RA). PBO data NR
RA
NR
−2.0 ± 6.2
−0.7 ± 7.6
Stern et al. 2004
10 wk.
PBO
NR
NR
−0.5 ± 0.8
“Repeated measures analysis for the improvement in total UPDRS score during the 10-week period showed a significant change for the RA 2 mg group but not for the 1 and 4 mg groups, compared with PBO”
RA 1 mg
NR
NR
−1.8 ± 1.3
RA 2 mg
NR
NR
−3.6±1.7
RA 4 mg
NR
NR
−3.6 ± 1.2
Values reported as mean ± standard deviation. NR = not reported, PBO = placebo, RA = rasagiline, wk = week, UPDRS = the unified Parkinson’s disease rating scale. aPost hoc analysis of the ADAGIO study [24]. Statistically significant results are highlighted using bold text.
